The pursuit of Bruton’s tyrosine kinase (BTK) inhibitors has long been viewed as a significant frontier in multiple sclerosis (MS) treatment, promising to modulate the immune system with greater precision than previous generations of therapy. New data from Roche suggests its candidate, fenebrutinib, is making a compelling case for that potential. According to findings presented this week, the drug more than doubled the relapse-free interval for patients when compared to Sanofi’s Aubagio, a standard oral therapy.
The efficacy results are among the most robust seen for this class of drugs. By demonstrating what researchers described as the "lowest relapse" rate in its category, fenebrutinib positions itself as a potent alternative for managing the unpredictable flares that define the MS experience. This clinical success is particularly noteworthy as other competitors in the BTK space have struggled to achieve such clear-cut results in late-stage trials.
However, the data also underscored a familiar complication: liver toxicity. The potential for liver injury has been a recurring shadow over the development of BTK inhibitors, and fenebrutinib appears to require similar vigilance. While the drug’s ability to stave off neurological decline is significant, the necessity for diligent monitoring suggests that its path to the pharmacy shelf will involve a careful weighing of neurological gains against systemic risks.
With reporting from Endpoints News.
Source · Endpoints News
